A novel marker ADAM17 for clear cell renal cell carcinomas: Implication for patients' prognosis

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 8, 2014, Pages 1272-1276

  Li, Guorong ^a,c   Forest, Fabien ^a   Feng, Gang ^b   Gentil Perret, Anne ^a   Péoc'h, Michel ^a   Cottier, Michèle ^a,c   Mottet, Nicolas ^a,c  

^a UNIVERSITÉ JEAN MONNET   (France)

^b WANNAN MEDICAL COLLEGE   (China)

^c Jean Monnet University   (France)

Author keywords

ADAM17; Immunohistochemistry; Prognosis; Renal cell carcinoma

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE 17; ADAM PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; TUMOR MARKER; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CYTOPLASM; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR LOCALIZATION; DISEASE FREE SURVIVAL; ENZYMOLOGY; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925934364     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.05.011     Document Type: Article

References (18)

1. Arribas J., Bech-Serra J.J., Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev 2006, 25:57-68.
2. Duffy M.J., McKiernan E., O'Donovan N., et al. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009, 15:1140-1144.
3. Borrell-Pages M., Rojo F., Albanell J., et al. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 2003, 22:1114-1124.
4. Kenny P.A., Bissell M.J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007, 117:337-345.
5. Lam J.S., Leppert J.T., Figlin R.A., et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005, 66:1-9.
6. Kim S.P., Weight C.J., Leibovich B.C., et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 2011, 78:1101-1106.
7. Franovic A., Robert I., Smith K., et al. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res 2006, 66:8083-8090.
8. Melenhorst W.B., Visser L., Timmer A., et al. ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability?. Am J Physiol Renal Physiol 2009, 297:F781-F790.
9. Moch H., Artibani W., Delahunt B., et al. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 2009, 56:636-643.
10. Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655-663.
11. Li G., Barthelemy A., Feng G., et al. S100A1: a powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma. Histopathology 2007, 50:642-647.
12. McGowan P.M., McKiernan E., Bolster F., et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol 2008, 19:1075-1081.
13. McGowan P.M., Ryan B.M., Hill A.D., et al. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res 2007, 13:2335-2343.
14. Shou Z.X., Jin X., Zhao Z.S. Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann Surg 2012, 256:1014-1042.
15. Zatovicova M., Sedlakova O., Svastova E., et al. Ectodomain shedding of the hypoxiainduced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 2005, 93:1267-1276.
16. Duffy M.J., Mullooly M., O'Donovan N., et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?. Clin Proteomic 2011, 8:9.
17. Coppin C, Kollmannsberger C, Le L, et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomized trials. BJU Int 2011, 108:1556-1563.
18. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.